Analysis of DOC and Ram for NSCLC
Yoshimura, Akihiro Kyoto Prefectural University of Medicine
Yamada, Tadaaki Kyoto Prefectural University of Medicine
Okuma, Yusuke Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Kitadai, Rui Tokyo Metropolitan Cancer and Infectious Diseases Center Komagome Hospital
Takeda, Takayuki Uji-Tokushukai Medical Center
Kanematsu, Takanori Matsuyama Red Cross Hospital
Yoneda, Hiroto Tokushima University Tokushima University Educator and Researcher Directory
Harada, Taishi Fukuchiyama City Hospital
Kubota, Yutaka Japanese Red Cross Kyoto Daini Hospital
Yamada, Takahiro Matsushita Memorial Hospital
Date, Koji Kyoto Chubu Medical Center
Shiotsu, Shinsuke Japanese Red Cross Kyoto Daiichi Hospital
Nagata, Kazuhiro Koseikai Takeda Hospital
Chihara, Yusuke Kyoto Prefectural University of Medicine
Kaneko, Yoshiko Kyoto Prefectural University of Medicine
Uchino, Junji Kyoto Prefectural University of Medicine
Nishioka, Yasuhiko Tokushima University Tokushima University Educator and Researcher Directory KAKEN Search Researchers
Takayama, Koichi Kyoto Prefectural University of Medicine
programmed death-ligand 1
non-small cell lung cancer (NSCLC)
Background: Current clinical trials demonstrated that combination regimens comprising chemotherapy and immunotherapy lead to better patient outcomes compared to chemotherapy alone as the first line of treatment for non-small cell lung cancer (NSCLC). In addition, the combination therapy of docetaxel (Doc) and ramucirumab (Ram) was considered one of the standard treatments for advanced or relapsed NSCLC patients. However, little is known about the therapeutic responders of this combination therapy among previously treated NSCLC patients. In the present study, we aimed to identify predictive factors for therapeutic response, including programmed death-ligand 1 (PD-L1) expression in tumors, for Doc treatment in combination with Ram.
Methods: We retrospectively analyzed a total of 135 advanced or relapsed NSCLC patients who were refractory to platinum-based chemotherapy at eleven institutions in Japan between July 2016 and November 2018.
Results: Our observations showed that PD-L1 expression in tumors is not associated with the efficacy of combined therapy of Doc and Ram in previously treated NSCLC patients. Analysis of the patient clinical profiles indicated that prior treatment with immune checkpoint inhibitors (ICIs) is a reliable predictor for the good progression-free survival (PFS) to this combination therapy (P=0.041).
Conclusions: Our retrospective study indicated that combination regimens comprising chemotherapy and ICIs followed by Doc and Ram could be an optimal therapeutic option for NSCLC patients regardless of the PD-L1 status of tumors. Further investigations are required to strengthen clinical evidence demonstrating the effectiveness of the combination therapy of Doc plus Ram in previously treated NSCLC patients.
Translational Lung Cancer Research
AME Publishing Company
This is an open access article under the CC BY-NC-ND license(http://creativecommons.org/licenses/by-nc-nd/4.0/)
|DOI (Published Version)|
|URL ( Publisher's Version )|
tlcr_8_4_450.pdf 879 KB